9 results about "Platelet adhesion" patented technology

This invention discloses a method for surface-modified biomaterials and a modified pericardial material, relating to the field of biomedical materials technology. The method includes the following steps: S1, providing animal pericardial material cross-linked with glutaraldehyde; providing a bridging molecule containing a first bridging group and a second bridging group, and a phosphorylcholine polymer with a third bridging group at its end; binding the first bridging group to an aldehyde group on the surface of the pericardial material via a first covalent reaction; binding the second bridging group to the third bridging group via a second covalent reaction, thereby achieving grafting of the phosphorylcholine polymer onto the material surface; the first covalent reaction and / or the second covalent reaction include Schiff base formation and reductive amination processes. The modified pericardial material prepared in this application introduces a phosphorylcholine biomimetic coating, which can improve blood compatibility on the material surface, reduce activation of the coagulation system and platelet adhesion, and inhibit the initiation of calcium ion deposition on the material surface, while exhibiting high safety.

This invention provides a method for preparing a deep vein catheter and its inner and outer walls with zwitterionic hydrogel coatings. The catheter of this invention includes: a catheter substrate; an adhesive coating covering the inner and outer walls of the catheter; an inner wall coating and an outer wall coating (4); wherein the inner wall coating and the outer wall coating are respectively fixed to the inner and outer surfaces of the catheter substrate by the adhesive coating; and both are zwitterionic hydrogel coatings. By simultaneously constructing this hydration barrier on the inner and outer walls of the catheter, this invention can block platelet adhesion and coagulation pathway activation from the initial stage of thrombosis; at the same time, the semi-interpenetrating network or microgel-reinforced structure significantly improves the mechanical stability and durability of the hydrogel, making it suitable for long-term indwelling catheters.

The invention relates to a filtration unit for enabling the selective leucocytapheresis of a fluid containing blood platelets. The filtration unit includes an external pouch provided with an inlet orifice and an outlet orifice, the pouch enclosing a porous element interposed between the orifices. The porous element encloses a leucocytapheresis medium impregnated with a polymer, the polymer having the general formula -(A)m-(B)n- (I), wherein A is a unit originating from an alkoxyalkyl acrylate or alkoxyalkyl methacrylate monomer, B is a unit originating from a hydrophobic polymerisable monomer, and m and n are integers, the sum of which, m+n, is equal to 100, m being an integer greater than 80.

The application discloses an enhanced anti-coagulation and anti-bacterial hemodialysis hollow fiber membrane and a preparation method thereof, and belongs to the technical field of medical membrane materials. The acid activation-polydopamine coating-sulfonated grafting modification of halloysite nanotubes is carried out in the application, so that the surface sulfonic acid group density of the halloysite nanotubes reaches 0.8-2.1 mmol / g, and the Zeta potential is less than or equal to-30 mV. The modified halloysite is dispersed in a polar aprotic solvent in advance, is incorporated into a polymer matrix after ultrasonic treatment, is filtered through a sintering filter element with a diameter of less than or equal to 5 mu m, is defoamed, is spun by using a dry spraying-wet spinning method, and is prepared into a finished product through coagulation, rinsing and drying. The application constructs a heparin-like negative charge layer, so that the activated partial thromboplastin time (APTT) is greater than or equal to 55 s, platelet adhesion and protein adsorption are significantly inhibited, and the application has a broad-spectrum antibacterial performance. The rigid halloysite induces the formation of through channels, so that the pain point that a high-flux membrane is easy to damage red blood cells is solved, the process is stable, and the application is suitable for industrial production.

The application discloses a multifunctional composite coating for a zinc-based implant, which is prepared on the surface of the zinc-based implant, and is prepared by using poly-tannic acid as a bottom layer and grafting epsilon-polylysine on the bottom layer through a covalent bond; the application also discloses a preparation method of the composite coating, which comprises the following steps: preparing a poly-tannic acid bottom layer on the surface of the zinc implant, and then grafting epsilon-polylysine to obtain a zinc-based implant with the multifunctional composite coating, and the zinc-based implant is applied to the field of implants related to biological and pharmaceutical materials. The multifunctional composite coating can induce platelet adhesion and activation, trigger a blood coagulation cascade reaction, and quickly form a stable blood coagulation layer to provide an ideal microenvironment for bone repair; meanwhile, the introduction of epsilon-polylysine enables the coating to have a strong and long-lasting contact antibacterial capacity, and the two can synergistically promote early osteogenesis; the preparation process is simple, the conditions are mild, the raw materials have good biocompatibility, and the multifunctional composite coating is suitable for surface functionalization modification of various implant instruments such as zinc-based bone nails, bone plates and bone scaffolds.

This invention relates to a medical device comprising at least one substrate having a coating, wherein the coating includes a functional layer situated on the substrate, wherein the functional layer comprises at least one sugar alcohol and is directly or indirectly bound to the substrate through the functionalization of the sugar alcohol. Optionally, the functional layer may also comprise other sugars, in which case it is crucial that the sugars polymerize only when bound to the substrate. The medical device of this invention exhibits reduced platelet adhesion and aggregation.

This invention belongs to the field of genetic engineering technology, specifically relating to a modular tandem repeat recombinant type III collagen with high platelet adhesion and its applications. The amino acid sequence of the recombinant type III collagen includes repeating units, with ≥3 repeating units; functional modules are inserted within each repeating unit. This invention integrates multiple discrete platelet-binding sites in type III collagen, designs a tandem repeat structure of different modular sequences (≥3 repeating units), optimizes spatial synergy, optimizes the gene sequence using codon bias, efficiently expresses the gene through a Pichia pastoris expression system, and obtains a high-purity product after purification. The recombinant type III collagen prepared by this invention exhibits good biocompatibility and can significantly promote erythrocyte and platelet adhesion; it can be widely used in wound repair, hemostatic materials, and tissue engineering.

The application belongs to the technical field of biological medicine, and particularly relates to a Buthus martensii Karsch (Buthus martensii Karsch) oligopeptide and application thereof in preparation of anti-platelet and anti-thrombus drugs or compositions. Buthus martensii The application discloses an anti-platelet oligopeptide discovered by combining an active-oriented separation with computer virtual screening based on a Karsch transcriptome database. The oligopeptide can not only inhibit platelet aggregation, but also effectively inhibit platelet adhesion and expansion. In a thrombus model experiment in vivo, the Buthus martensii Karsch oligopeptide discovered by the application can well inhibit FeCl3-induced carotid artery thrombosis of a mouse. Meanwhile, it is found that the Buthus martensii Karsch oligopeptide does not have obvious bleeding tendency. In conclusion, the Buthus martensii Karsch oligopeptide can be used as an anti-platelet aggregation and anti-thrombus drug to play a certain positive role in the prevention and treatment of thrombotic diseases.